SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NexStar Pharm(NXTR)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
328 5 0 NXTR
Emcee:  Miljenko Zuanic Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
278 mz, They claim US launch was "in line with our expectations." Must nBiomaven-3/4/1998
277 Nexstar reported 4Q/Y results: biz.yahoo.com AmBisome sale in US are not goodMiljenko Zuanic-3/4/1998
276 Is anyone out there any more? NXTR seems to be basing nicely at the 11.50 - 12John Veltheer-2/25/1998
275 To ALL: Does anyone know when NXTR is going to release its 97Q4 result? The cSteven Yang-2/3/1998
274 13G/A file by S.W.I.B.on 1-22-98: They increase NXTR holding from 8.5% (2,237,Miljenko Zuanic-1/28/1998
273 Thanks Peter. I sow news few days ago, and this today repeat do not fit well wMiljenko Zuanic-1/23/1998
272 Miljenko: NXTR acquires Perseptive patents: biz.yahoo.com PeterBiomaven-1/23/1998
271 TD: I heard about PM and their diabetes program. I am not following diagnosticMiljenko Zuanic-1/19/1998
270 MZ, I mentioned I was long two biotechs(LGND & Xoma) but the company that IArthur Radley-1/19/1998
269 Thanks and good luck with Ligand and Xoma. mzMiljenko Zuanic-1/18/1998
268 mz, thanks for another in-depth post. I walked through all the older posts of james-1/18/1998
267 >>>so one more time, good luck to all shorts>> I am not long or Arthur Radley-1/18/1998
266 James: NXTR AmBisome, MiKasome, LipoCephalosphorin, and other are side line drMiljenko Zuanic-1/18/1998
265 Thanks TD. I sow street.com article and my opinion is that J.E. is poorly infoMiljenko Zuanic-1/18/1998
264 This information was gleened from TheStreet.com and their biotech reporter, JesArthur Radley-1/18/1998
263 The most interesting aspect of nxtr's selex tech is quoted from the pnas pajames-1/17/1998
262 TD: What is source of this word/rumor? As far as I know treatment cost is ~30Miljenko Zuanic-1/17/1998
261 A stock that I think has alot of potential in the diabetes supply area is PolyMArthur Radley-1/17/1998
260 TD, thx again. $900 to $240? sure doesn't look too good. Wondering what thojames-1/17/1998
259 James, The word/rumor is that Nexstar is having problems selling their AmbisoneArthur Radley-1/17/1998
258 TD, thx. I noticed nxtr while reading some old papers in pnas pnas.org. nxtr&james-1/17/1998
257 James, Short interest is the number of shares that have been sold short with thArthur Radley-1/17/1998
256 mz, just found this info about short interests in nxtr (No. 5) & isip (No. james-1/17/1998
255 Lipo report small increase in Abelcet sales (4Q 15.66M compared to 3Q 13.1M), Miljenko Zuanic-1/15/1998
254 Hi Michael: Thanks for info. From Insider Trading Summaries transaction priceMiljenko Zuanic-12/17/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News